Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial.
about
Telomere and Telomerase Therapeutics in CancerSurvivin: a unique target for tumor therapyEngineering opportunities in cancer immunotherapyTargeting survivin in cancerTwelve-year survival and immune correlates in dendritic cell-vaccinated melanoma patients.Efficient transduction of myeloid cells by an HIV-1-derived lentiviral vector that packages the Vpx accessory proteinIdentification of a cyclin B1-derived CTL epitope eliciting spontaneous responses in both cancer patients and healthy donors.Immunological and clinical effects of vaccines targeting p53-overexpressing malignancies.A combination dual-sized microparticle system modulates dendritic cells and prevents type 1 diabetes in prediabetic NOD mice.Nanoparticle-Based Manipulation of Antigen-Presenting Cells for Cancer Immunotherapy.Trial watch: Dendritic cell-based interventions for cancer therapyPrioritization schema for immunotherapy clinical trials in glioblastoma.Current status and future applications of cellular therapies for cancer.Survivin in skin pathologies.Immunotherapy for metastatic melanoma.Survivin signaling in clinical oncology: a multifaceted dragon.Dendritic cell engineering for tumor immunotherapy: from biology to clinical translation.Nanotechnology based platforms for survivin targeted drug discovery.Cancer stem cell antigen-based vaccines: the preferred strategy for active specific immunotherapy of metastatic melanoma?Kill and spread the word: stimulation of antitumor immune responses in the context of radiotherapy.Dendrimers as nonviral vectors in dendritic cell-based immunotherapies against human immunodeficiency virus: steps toward their clinical evaluation.Cellular immunotherapy of cancer: an overview and future directions.Development of a potent melanoma vaccine capable of stimulating CD8(+) T-cells independently of dendritic cells in a mouse model.Matrine activates PTEN to induce growth inhibition and apoptosis in V600EBRAF harboring melanoma cells.DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model.The gene expression profile of unstimulated dendritic cells can be used as a predictor of function.Canine cutaneous melanocytic tumours: significance of β-catenin and survivin immunohistochemical expression.mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma.GK-1 improves the immune response induced by bone marrow dendritic cells loaded with MAGE-AX in mice with melanoma.Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein.Trial Watch: Peptide vaccines in cancer therapy.FDG PET scans as evaluation of clinical response to dendritic cell vaccination in patients with malignant melanoma.Generation of autologous tumor-specific T cells for adoptive transfer based on vaccination, in vitro restimulation and CD3/CD28 dynabead-induced T cell expansion.Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS
P2860
Q26744808-66FD5362-B66C-4F6C-9B88-434E9A807EE2Q26747332-5389E5EA-0A3A-4420-8821-98D8425A0B80Q26776373-DBF4C62B-6B86-4CA0-929F-D54EE763F215Q27012954-13B0AB25-72C8-442E-B60E-6CC8CA0D47CCQ30846001-B63E9BEA-A8C8-4FD3-8F0F-A4D6B29DBBB0Q33926275-A3840D04-48EC-4C28-9607-D3338FC2CD4DQ34508082-FB51A87A-A6A5-424C-B9B2-0C6C12217148Q34898280-F97589F3-067F-4190-AF6F-32309994391DQ36011349-ABA6A33D-2B30-431C-B805-CCC86C75EF61Q36269694-274CAC7F-B017-4A5D-B248-BA6CA7677A1AQ36388529-D16FB7E7-3C18-4CA6-A21E-96CD5CA8DDB4Q37078999-B3896EE3-061D-4F36-95DA-0092DB3328E2Q37861216-BA13E04E-A563-462B-9A81-3D4DC45FD0D5Q37876468-F7442EEA-2F39-4C26-9AA3-ABA15EA5792EQ37946772-024CB48A-8589-4F67-BEBA-97B23B4A2B54Q38017923-25EC8B7E-ACB3-4DA9-95B0-7CBB5051BAF8Q38031280-9A7F6270-BC4A-44BC-A0C9-CAD8E123932DQ38040859-80B89DE1-448B-4CD6-B3DC-2410D1EAF529Q38085677-23CFE012-582E-4630-B2F1-8E66F22EAE28Q38217593-A0145B91-17D1-4883-BC57-2524EB1B62B9Q38296086-E2ADE887-170F-4093-91BE-68F1A7CD79ECQ38673161-174C42F0-975C-4377-8817-3F008525565CQ38884592-BE1AC801-7E66-4E3E-BC26-A6A230182121Q39115959-634F4416-E7BD-4BFC-BA37-9A487CC08786Q39329856-49936ADA-A54C-403B-85EF-125A5207D16BQ39566639-10E1C163-F8FB-4FE1-8834-C317C35B2D78Q40951477-EB5E1EC1-7834-4731-BE40-18D1A3FD6B27Q41297982-FFE321DA-D96D-4892-BC31-751C1B1BB6C2Q41901253-B8FE36BB-4536-4EBB-971E-B522C19F77B8Q41976096-430057AF-2998-40CE-98DE-F2C374E2264DQ42734544-6CB038D8-00F4-46D4-909E-46D8FB5BC2BBQ46165601-82DED0D2-CFFB-41D2-8640-327F24C2BC41Q50973652-09BA8F5F-E8C5-419D-9735-D29080612DFCQ57159575-10972085-E3CA-458B-8D8A-DE7B8B9CDF6D
P2860
Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Vaccination with autologous de ...... sults from a phase I/II trial.
@en
Vaccination with autologous de ...... sults from a phase I/II trial.
@nl
type
label
Vaccination with autologous de ...... sults from a phase I/II trial.
@en
Vaccination with autologous de ...... sults from a phase I/II trial.
@nl
prefLabel
Vaccination with autologous de ...... sults from a phase I/II trial.
@en
Vaccination with autologous de ...... sults from a phase I/II trial.
@nl
P2093
P50
P1433
P1476
Vaccination with autologous de ...... sults from a phase I/II trial.
@en
P2093
Amir Soleimani
Annika Berntsen
Julia S Johansen
Poul F Geertsen
Redas Trepiakas
Torben Lorentzen
P304
P356
10.3109/14653241003774045
P577
2010-10-01T00:00:00Z